When was Spur Therapeutics founded?

Spur Therapeutics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Spur Therapeutics located?

Spur Therapeutics is headquartered in Stevenage, United Kingdom.

Who is the current CEO of Spur Therapeutics?

Michael Parini of Spur Therapeutics.

How many employees does Spur Therapeutics have?

As of Sep 30, 2026, the latest employee count at Spur Therapeutics is 278.

Is Spur Therapeutics a funded company?

Spur Therapeutics is a funded company, having raised a total of $274M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 2015.

When was the latest funding round of Spur Therapeutics?

Spur Therapeutics' latest funding was a $***** Post IPO round on Aug 14, 2020, with participation from 0 investor. Its primary sector is Neurology. In United Kingdom, the Neurology sector has seen $454M in funding in 2026 to date.

Where does Spur Therapeutics rank among its competitors?

Spur Therapeutics ranks 247th amongst 2997 active competitors, of which 1001 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Spur Therapeutics?

Spur Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Spur Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Spur Therapeutics is an acquired company based in Stevenage (United Kingdom), founded in 2015. It operates as a Developer of gene therapies for debilitating chronic diseases. Spur Therapeutics has raised $274M in funding from investors like Syncona, Wellington and Novo Holdings. The company has 2997 active competitors, including 1001 funded and 722 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of gene therapies for debilitating chronic diseases. The company is enhancing gene expression and targeted delivery to develop the next generation of gene therapy, with a pipeline targeting various diseases, including Parkinson's and Gaucher's.

Website: spurtherapeutics.com
Social
Email ID: *****@spurtherapeutics.com

Key Metrics

Founded Year

2015

Location

Stevenage, United Kingdom

Stage

Acquired

Total Funding

$274M in 6 rounds

Latest Funding Round

Post IPO, Aug 14, 2020, $*****

Investors

Syncona & 9 more

Ranked

247^th among 2997 active competitors

Employee Count

278 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 694 more

Exit Details

Acquired by Syncona (Nov 22, 2023)

View Spur Therapeutics' full profile

Spur Therapeutics got acquired by Syncona on Nov 22, 2023.

Click here to take a look at Spur Therapeutics's acquisition in detail

Spur Therapeutics has raised a total funding of $274M over 6 rounds. Its first funding round was on Dec 2015. Spur Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Spur Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 14, 2020	9632017	Post IPO	8216535	8313635	3016939	2525692
Jun 30, 2020	5620490	Series C	2930418	9230495	8396769	Acorn Bioventures & 1 more
Dec 19, 2019	7340029	Series C	4606930	2889932	Syncona	4273453

Access funding benchmarks and valuations. Sign up today!

View details of Spur Therapeutics's funding rounds and investors

Spur Therapeutics' employee count trend

Spur Therapeutics has 278 employees as of Sep 26. Here is Spur Therapeutics's employee count trend over the years:

Employee count trend for Spur Therapeutics

Uncover Spur Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spur Therapeutics include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Spur Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 29 others	73/100
4th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 11 others	70/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
247th	Spur Therapeutics 2015, Stevenage (United Kingdom), Acquired	Developer of gene therapies for debilitating chronic diseases	$274M	Cowen, Wellington & 8 others	57/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Spur Therapeutics's competitors? Click here to see the top ones

Spur Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Spur Therapeutics's sector:

Free

Neurology - Sector Report

Edition: September, 2026 (73 Pages)

View all reports related to Spur Therapeutics

Media has covered Spur Therapeutics for a total of 3 events in the last 1 year, 2 of them have been about company updates and 1 about people movement.